{"doi":"10.7554/elife.06535","title":"Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism","abstract":"<jats:p>CDK9 is the kinase subunit of positive transcription elongation factor b (P-TEFb) that enables RNA polymerase (Pol) II's transition from promoter-proximal pausing to productive elongation. Although considerable interest exists in CDK9 as a therapeutic target, little progress has been made due to lack of highly selective inhibitors. Here, we describe the development of i-CDK9 as such an inhibitor that potently suppresses CDK9 phosphorylation of substrates and causes genome-wide Pol II pausing. While most genes experience reduced expression, MYC and other primary response genes increase expression upon sustained i-CDK9 treatment. Essential for this increase, the bromodomain protein BRD4 captures P-TEFb from 7SK snRNP to deliver to target genes and also enhances CDK9's activity and resistance to inhibition. Because the i-CDK9-induced MYC expression and binding to P-TEFb compensate for P-TEFb's loss of activity, only simultaneously inhibiting CDK9 and MYC/BRD4 can efficiently induce growth arrest and apoptosis of cancer cells, suggesting the potential of a combinatorial treatment strategy.</jats:p>","journal":"eLife","year":2015,"id":619975,"datarank":0.7593892549540452,"base_score":5.062595033026967,"endowment":5.062595033026967,"self_citation_contribution":0.7593892549540452,"citation_network_contribution":0.0,"self_endowment_contribution":0.7593892549540452,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":157,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":406265,"name":"Yuhua Xue","orcid":"0000-0001-5804-5162","position":1,"is_corresponding":false},{"id":1600220,"name":"Guoying K Yu","orcid":null,"position":2,"is_corresponding":false},{"id":1238514,"name":"Carolina Arias","orcid":"0000-0002-4445-0826","position":3,"is_corresponding":false},{"id":859117,"name":"Julie Lin","orcid":"0000-0001-9496-9389","position":4,"is_corresponding":false},{"id":1600221,"name":"Susan Fong","orcid":null,"position":5,"is_corresponding":false},{"id":165086,"name":"Michel Faure","orcid":null,"position":6,"is_corresponding":false},{"id":997,"name":"Ben Weisburd","orcid":"0000-0001-9898-9109","position":7,"is_corresponding":false},{"id":1600222,"name":"Xiaodan Ji","orcid":null,"position":8,"is_corresponding":false},{"id":287756,"name":"Alexandre Mercier","orcid":"0009-0005-1651-334X","position":9,"is_corresponding":false},{"id":1600223,"name":"James Sutton","orcid":null,"position":10,"is_corresponding":false},{"id":1600224,"name":"Kunxin Luo","orcid":null,"position":11,"is_corresponding":false},{"id":1600225,"name":"Zhenhai Gao","orcid":null,"position":12,"is_corresponding":false},{"id":1127107,"name":"Qiang Zhou","orcid":"0000-0003-3697-9348","position":13,"is_corresponding":false},{"id":710079,"name":"Huasong Lu","orcid":"0000-0003-0875-5531","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism","abstract":"<jats:p>CDK9 is the kinase subunit of positive transcription elongation factor b (P-TEFb) that enables RNA polymerase (Pol) II's transition from promoter-proximal pausing to productive elongation. Although considerable interest exists in CDK9 as a therapeutic target, little progress has been made due to lack of highly selective inhibitors. Here, we describe the development of i-CDK9 as such an inhibitor that potently suppresses CDK9 phosphorylation of substrates and causes genome-wide Pol II pausing. While most genes experience reduced expression, MYC and other primary response genes increase expression upon sustained i-CDK9 treatment. Essential for this increase, the bromodomain protein BRD4 captures P-TEFb from 7SK snRNP to deliver to target genes and also enhances CDK9's activity and resistance to inhibition. Because the i-CDK9-induced MYC expression and binding to P-TEFb compensate for P-TEFb's loss of activity, only simultaneously inhibiting CDK9 and MYC/BRD4 can efficiently induce growth arrest and apoptosis of cancer cells, suggesting the potential of a combinatorial treatment strategy.</jats:p>","is_dataset_classified":null,"base_score":5.062595033026967,"endowment":5.062595033026967,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26083714","pmcid":"PMC4490784","openalex_id":"https://openalex.org/W1834739414","authors":[],"funders":[{"funder_name":"National Institutes of Health (NIH)","grant_id":"R01AI41757","title":null},{"funder_name":"National Institutes of Health (NIH)","grant_id":"R01AI095057","title":null},{"funder_name":"U.S. Department of Defense","grant_id":"W81XWH-15-1-0067","title":null},{"funder_name":"U.S. Department of Defense","grant_id":"W81XWH-15-1-0068","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"81201276","title":null},{"funder_name":"NIAID NIH HHS","grant_id":"R01 AI041757","title":null},{"funder_name":"National Institutes of Health","grant_id":"5R01AI041757-07","title":"Regulation of Transcriptional Elongation by HIV-1 TAT"},{"funder_name":"National Institutes of Health","grant_id":"1R01AI095057-01","title":"Tat cofactors and control of HIV-1 latency"}],"total_grants":8,"fwci":5.2371,"citation_percentile":0.96402821,"influential_citations":0,"citation_trend":[{"year":2015,"count":2},{"year":2016,"count":13},{"year":2017,"count":9},{"year":2018,"count":14},{"year":2019,"count":17},{"year":2020,"count":22},{"year":2021,"count":14},{"year":2022,"count":14},{"year":2023,"count":15},{"year":2024,"count":16},{"year":2025,"count":15},{"year":2026,"count":6}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.7554/elife.06535","host_type":"journal"},{"url":"https://doi.org/10.7554/elife.06535","host_type":"publisher"},{"url":"http://elifesciences.org/lookup/doi/10.7554/eLife.06535","host_type":"publisher"},{"url":"https://cdn.elifesciences.org/articles/06535/elife-06535-v2.pdf","host_type":"publisher"},{"url":"https://cdn.elifesciences.org/articles/06535/elife-06535-v2.xml","host_type":"publisher"},{"url":"https://elifesciences.org/articles/06535","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26083714","host_type":"repository"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26186095","host_type":"repository"},{"url":"https://doaj.org/article/b1b42b620f7c43a4aabed62fe96ce872","host_type":"repository"},{"url":"https://escholarship.org/uc/item/4mq9k563","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4490784","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4502752","host_type":"repository"},{"url":"http://doi.org/10.7554/eLife.06535","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC4490784","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC4490784?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.7554/eLife.06535","host_type":""},{"url":"https://dx.doi.org/10.7554/elife.06535","host_type":""},{"url":"https://escholarship.org/content/qt4mq9k563/qt4mq9k563.pdf","host_type":""},{"url":"https://doi.org/https://doi.org/10.7554/elife.06535","host_type":""}],"fields_of_study":["Protein Degradation and Inhibitors","Genomics and Chromatin Dynamics","Ubiquitin and proteasome pathways","0301 basic medicine","03 medical and health sciences","0303 health sciences","Cell Cycle Proteins","Cyclin-Dependent Kinase 9","Gene Expression Regulation","Humans","Nuclear Proteins","Positive Transcriptional Elongation Factor B","Proto-Oncogene Proteins c-myc","Transcription Factors","Bromodomain Containing Proteins"],"mesh_terms":["Bromodomain Containing Proteins","Gene Expression Regulation","Humans","Nuclear Proteins","Transcription Factors","Proto-Oncogene Proteins c-myc","Cell Cycle Proteins","Cyclin-Dependent Kinase 9","Positive Transcriptional Elongation Factor B"],"keywords":["P-TEFb","BRD4","RNA polymerase II","Cyclin-dependent kinase 9","Bromodomain","Biology","Cell biology","Gene expression","Molecular biology","Kinase","Chemistry","Protein kinase A","Gene","Cyclin-dependent kinase 2","Histone","Biochemistry","Promoter","Genes","Human","MYC","CDK9","chromosomes","Transcriptional Elongation","Cdk9 Inhibitor","Rna Polymerase Pause And Release","Biomedical and clinical sciences","QH301-705.5","Science","610","Cell Cycle Proteins","Proto-Oncogene Proteins c-myc","Bromodomain Containing Proteins","Genetics","Humans","Positive Transcriptional Elongation Factor B","Biology (General)","Cancer","Q","R","Health sciences","Nuclear Proteins","Biological Sciences","Gene Expression Regulation","5.1 Pharmaceuticals","Medicine","Biochemistry and Cell Biology","Generic health relevance","Transcription Factors"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":12,"sdg_label":"12. Responsible consumption"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"geo"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T09:27:23.057857Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}